Clinical Trials
3 trialsNCT07554898 2026-05-11
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage â… -â…¡ MALT Lymphoma
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07480863 2026-04-02
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06793189 2026-03-24
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Recruiting